{
    "clinical_study": {
        "@rank": "72355", 
        "acronym": "BIOPARK", 
        "arm_group": [
            {
                "arm_group_label": "Parkinson's disease patients", 
                "description": "Patients suffering from Parkinson desease"
            }, 
            {
                "arm_group_label": "multiple system atrophy patients", 
                "description": "Patients suffering from \"probable\" multiple system atrophy according to clinical consensus criteria and age > 30"
            }, 
            {
                "arm_group_label": "progressive supranuclear palsy", 
                "description": "Patients suffering from progressive supranuclear palsy and age > 40"
            }
        ], 
        "biospec_descr": {
            "textblock": "-  Cerebrospinal fluid\n\n        -  Whole blood\n\n        -  Plasma\n\n        -  Serum\n\n        -  Urine"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy\n      (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are\n      characterized by the abnormal accumulation of alpha-synuclein, while tau protein accumulates\n      in PSP. The development of biological markers for the diagnosis and prognosis in PD, MSA and\n      PSP remains an unmet need. Such biological markers are crucial for future\n      disease-modification and neuroprotection trials. Alpha-synuclein has a high potential for\n      biomarker development since it constitutes the pathological hallmark feature in PD and MSA.\n      The oligomeric alpha-synuclein seems to be particularly involved in abnormal protein\n      aggregation in alpha-synucleinopathies.\n\n      The main objective is to compare oligomeric alpha-synuclein CSF levels between PD, MSA and\n      PSP patients. PD and MSA patients will receive Cerebrospinal Fluid (CSF) and blood sampling\n      at two study visits (baseline and after 12 months). Major secondary objectives are (i) to\n      assess potential associations between the biomarker and clinical measures of disease\n      severity and progression in MSA and PSP, and (ii) to assess the variation of the biomarker\n      and its correlation to disease severity and progression in PD, MSA and PSP."
        }, 
        "brief_title": "Biomarkers in Parkinsonian Syndromes", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Parkinsonian Syndromes", 
            "Parkinson's Disease", 
            "Multiple System Atrophy", 
            "Progressive Supranuclear Palsy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Parkinson Disease", 
                "Multiple System Atrophy", 
                "Shy-Drager Syndrome", 
                "Supranuclear Palsy, Progressive", 
                "Parkinsonian Disorders", 
                "Atrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "The differential diagnosis between Parkinson's disease, multiple system atrophy and\n      progressive supranuclear palsy can be very difficult in early disease. PD, MSA and PSP are\n      neurodegenerative disorders. PD and MSA belong to the alpha-synucleinopathies, which are\n      characterized by the abnormal accumulation of alpha-synuclein. Alpha-synuclein accumulates\n      in intraneuronal Lewy bodies in PD patients and as intracytoplasmic glial inclusions in MSA.\n      In PSP, tau protein accumulates in neurons and glia cells while alpha-synuclein deposits are\n      only found to a small extend.\n\n      The development of biological markers for the diagnosis and prognosis of PD, MSA and PSP\n      remains an unmet need. Beyond guiding clinical decision-making, such biological markers are\n      crucial for future disease-modification and neuroprotection trials.\n\n      Alpha-synuclein has a high potential for biomarker development since it constitutes the\n      pathological hallmark feature of PD and MSA. The oligomeric alpha-synuclein fraction whose\n      CSF levels are increased in PD seems to be particularly involved in abnormal protein\n      aggregation in alpha-synucleinopathies.\n\n      The main objective of the study is to compare oligomeric alpha-synuclein CSF levels between\n      PD, MSA and PSP patients. Secondary objectives are (i) to compare total alpha-synuclein\n      levels and the index total/oligomeric alpha-synuclein between PD, MSA and PSP, (ii) to study\n      the correlation and concordance between CSF and plasma levels of total and oligomeric\n      alpha-synuclein, (iii) to assess potential associations between the biomarker and clinical\n      measures of disease severity and progression and (iv) to assess the variation of the\n      biomarker over time and its correlation to disease severity and progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  PD patients\n\n               -  inclusion criteria:\n\n                    -  Patients suffering from PD according to clinical criteria (Hughes et al,\n                       1992)\n\n                    -  Written informed consent\n\n                    -  Patient covered by the national health system\n\n               -  exclusion criteria:\n\n                    -  Patient under tutelage\n\n                    -  patient covered by the national health system\n\n          -  MSA patients\n\n               -  inclusion criteria:\n\n                    -  Patients suffering from \"probable\" MSA according to clinical consensus\n                       criteria (Gilman et al, 2008), age > 30\n\n                    -  Written informed consent\n\n                    -  Patient covered by the national health system\n\n               -  exclusion criteria:\n\n                    -  UMSARS IV score >4 points\n\n                    -  Patient under tutelage\n\n          -  PSP patients\n\n               -  inclusion criteria:\n\n                    -  Patients suffering from PSP according to NNIPPS trial criteria (Bensimon et\n                       al., 2009), age > 40\n\n                    -  Written informed consent\n\n                    -  Patient covered by the national health system\n\n               -  exclusion criteria:\n\n                    -  PSPRS item 26 score >3 points\n\n                    -  Patient under tutelage"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients suffering from parkinson disease or multiple system atrophy or progressive\n        supranuclear palsy."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02114242", 
            "org_study_id": "CHUBX 2012/27"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "multiple system atrophy patients", 
                    "progressive supranuclear palsy"
                ], 
                "description": "PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).", 
                "intervention_name": "CSF, blood and urine sampling", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Parkinson's disease patients", 
                    "multiple system atrophy patients", 
                    "progressive supranuclear palsy"
                ], 
                "description": "Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)", 
                "intervention_name": "clinical measures of disease severity and progression", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Parkinson's disease", 
            "multiple system atrophy", 
            "progressive supranuclear palsy", 
            "alpha-synuclein"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Fr\u00e9d\u00e9ric Torny, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France", 
                        "zip": "87000"
                    }, 
                    "name": "CHU de Limoges"
                }, 
                "investigator": [
                    {
                        "last_name": "Fr\u00e9d\u00e9ric Torny, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Philippe Couratier, Pr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Wassilios MEISSNER, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Pessac", 
                        "country": "France", 
                        "zip": "33640"
                    }, 
                    "name": "CHU de Bordeaux"
                }, 
                "investigator": [
                    {
                        "last_name": "Wassilios MEISSNER, Pr", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Fran\u00e7ois TISON, Pr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Alexandra Foubert-Samier, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Olivier Flabeau, Md", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Olivier RASCOL, Pr"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31000"
                    }, 
                    "name": "CHU de Toulouse"
                }, 
                "investigator": [
                    {
                        "last_name": "Olivier RASCOL, PR", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Anne Pavy-Le Traon, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Christine Brefel-Courbon, Dr", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fabienne Ory-Magne, Dr", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "3", 
        "official_title": "Development of Biomarkers for the Diagnosis and Prognosis of Parkinsonian Syndromes Running Head: Biomarkers in Parkinsonian Syndromes", 
        "overall_contact": {
            "email": "wassilios.meissner@chu-bordeaux.fr", 
            "last_name": "Wassilios MEISSNER, Pr"
        }, 
        "overall_official": [
            {
                "affiliation": "Bordeaux University Hospital", 
                "last_name": "Wassilios MEISSNER, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Bordeaux university hospital", 
                "last_name": "Rodolphe THIEBAUT, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Concentration of oligomeric alpha-synuclein in cerebrospinal fluid", 
            "safety_issue": "No", 
            "time_frame": "at day 0 (inclusion) and one year after inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02114242"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total alpha-synuclein concentration in CSF, oligomeric/total alpha-synuclein ratio in CSF", 
                "safety_issue": "No", 
                "time_frame": "At inclusion (Day 0) and one year after inclusion"
            }, 
            {
                "measure": "Oligomeric and total alpha-synuclein concentration in plasma, oligomeric/total alpha-synuclein ratio in plasma", 
                "safety_issue": "No", 
                "time_frame": "At inclusion (Day 0) and one year after inclusion"
            }, 
            {
                "measure": "Alpha-synuclein levels in relation to disease severity and progression, disease duration and age", 
                "safety_issue": "No", 
                "time_frame": "At inclusion (Day 0) and one year after inclusion"
            }, 
            {
                "measure": "Variation of alpha-synuclein levels between first and second sampling", 
                "safety_issue": "No", 
                "time_frame": "At inclusion (Day 0) and one year after inclusion"
            }
        ], 
        "source": "University Hospital, Bordeaux", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Bordeaux", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}